The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. ICPO supports a new era of cancer care by scaling global patient access to Theranostics through a network of ICPO Theranostics Centers of Excellence and strong partnerships enabling innovation adoption. In January 2026, ICPO published its first Impact Report highlighting key milestones, global growth, and measurable progress.
To stay informed about new publications, please subscribe to the Newsletter of the ICPO Foundation here.
Impact Report 2025 of the ICPO Foundation
2025 was a breakthrough year for ICPO, emerging as a truly global non-profit player in Theranostics. The foundation has made meaningful progress for cancer patients worldwide, focusing on improved patient access to Theranostics and better clinical outcomes.
Supporting Theranostics centers globally, it enhances clinical practice, accelerates education, and fosters innovation. ICPO has developed a unique strategy that takes into account regional and national realities and the different maturity levels of Theranostics centers.
This approach is further strengthened by strong partnerships with leading medical societies, scientific experts, non-profit organizations, patient associations, governmental institutions, and industry leaders.
In 2025, ICPO significantly expanded its international network of Clinical Theranostics Centers of Excellence, growing from 11 centers in 2024 to over 50 in 2025, with the aim to double this number in 2026.
To further amplify its mission, ICPO became a co-founding member of the RLT Angels Association in 2025, alongside the European Association of Nuclear Medicine (EANM) and industry partners GE Healthcare, Novartis, and RayzeBio, a Bristol Myers Squibb company.
With best wishes,
Your ICPO Foundation team